Learn about CARVYKTI®, a type of CAR-T cell therapy for adult patients. See Safety & Prescribing information, including Boxed Warning. CARVYKTI ® (ciltacabtagene autoleucel) is …

Ciltacabtagene autoleucel, sold under the brand name Carvykti, is an anti-cancer medication used to treat multiple myeloma. [8] [10] [12] [13] Ciltacabtagene autoleucel is a BCMA (B-cell …

2022年3月30日 · Patients with advanced multiple myeloma now have a second option for CAR T-cell therapy, a type of personalized immunotherapy. On February 28, the Food and Drug …

2024年7月31日 · Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an …

2024年4月6日 · CARVYKTI ® (cilta-cel) received U.S. Food and Drug Administration approval in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after …

Carvykti是一种靶向B细胞成熟抗原（BCMA）的嵌合抗原受体T细胞（CAR-T）疗法，使用嵌合抗原受体（CAR）的转基因对患者自身的T细胞进行修饰，以识别和消除表达BCMA的细胞。 …

2022年4月11日 · CARVYKTI是一款具有两种靶向B细胞成熟抗原（BCMA）单域抗体的嵌合抗原受体 (CAR) T细胞免疫疗法，以一次性输液的方式给药，推荐剂量为每公斤体重0.5~1.0×106 …

Carvykti is a medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory).

Learn about CARVYKTI®, including what it is, how it works, patient response in a clinical study, safety, and more. See Safety & Prescribing info, including Boxed Warning. CARVYKTI ® …

1 天前 · CARVYKTI® (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of adult …